Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OGEN .625 vs AMNESTROGEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Estrogen replacement therapy; estrogen binds to estrogen receptors, which then translocate to the nucleus and modulate gene transcription, leading to effects such as proliferation of the endometrium and regulation of gonadotropin secretion.
Estrogen replacement therapy; binds to estrogen receptors, activating gene transcription and promoting development and maintenance of female reproductive tissues and secondary sex characteristics.
Treatment of moderate to severe vasomotor symptoms due to menopause,Treatment of vulvar and vaginal atrophy due to menopause,Prevention of postmenopausal osteoporosis
Treatment of moderate to severe vasomotor symptoms due to menopause,Treatment of vulvar and vaginal atrophy due to menopause,Prevention of postmenopausal osteoporosis,Estrogen replacement therapy in female hypogonadism,Palliative treatment of advanced breast cancer in selected postmenopausal women,Palliative treatment of advanced prostate cancer
0.625 mg orally once daily
1 tablet (2.5 mg estradiol and 0.625 mg norgestimate) orally once daily
Estrone: 10-24 hours; equilin: 12-18 hours; terminal half-life supports once-daily dosing.
Terminal elimination half-life is 13-18 hours; steady-state achieved after 5-7 days.
Primarily metabolized in the liver via CYP3A4; undergoes first-pass metabolism including sulfation and glucuronidation. Estropipate is hydrolyzed to estradiol and then metabolized.
Hepatic metabolism via cytochrome P450 enzymes (CYP3A4 and others); undergoes enterohepatic recirculation.
Renal (primarily as glucuronide and sulfate conjugates, ~50-80% of a dose), fecal (~10-20%), with enterohepatic recirculation.
Primarily renal (90-95%) as glucuronide and sulfate conjugates; biliary/fecal elimination accounts for <5%.
~50-80% bound to sex hormone-binding globulin (SHBG) and albumin.
98% bound primarily to albumin and sex hormone-binding globulin (SHBG).
Estrone: ~1-2 L/kg; indicates extensive tissue distribution.
1.0-1.5 L/kg; indicates extensive tissue distribution and binding.
Oral: ~30-50% due to first-pass metabolism; micronized formulation enhances absorption.
Oral: 2-10% due to first-pass metabolism; IM: 100%; Transdermal: 5-15%; Vaginal: 5-25%.
No dose adjustment required for GFR ≥30 m L/min; insufficient data for GFR <30 m L/min, use with caution
No specific dose adjustment required; use with caution in severe impairment (e GFR <30 m L/min/1.73m²) due to potential fluid retention
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated
Contraindicated in Child-Pugh class B and C; for class A, use lowest effective dose with monitoring
Not indicated for use in pediatric patients
Not indicated for pediatric use; safety and efficacy not established
Use lowest effective dose; monitor for thromboembolic events and malignant neoplasms; no specific dose adjustment recommended
Use lowest effective dose for shortest duration; increased risk of stroke, dementia, and breast cancer; consider alternative therapies
Estrogens increase the risk of endometrial carcinoma in postmenopausal women. Also, estrogens should not be used to prevent cardiovascular disease or dementia. Increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis have been reported with estrogen-alone therapy.
Estrogens increase the risk of endometrial cancer in postmenopausal women with an intact uterus. Estrogen-progestin therapy increases the risk of cardiovascular events, breast cancer, and probable dementia. Estrogen-alone therapy increases the risk of stroke and deep vein thrombosis.
Increased risk of endometrial cancer; cardiovascular disorders (MI, stroke, VTE); probable dementia; breast cancer; gallbladder disease; hypercalcemia; fluid retention; visual abnormalities; hereditary angioedema; exacerbation of asthma, diabetes, epilepsy, migraine, porphyria, SLE, and hepatic hemangiomas; hypothyroidism; elevated triglycerides; and hypersensitivity reactions.
Cardiovascular disorders (stroke, MI, thromboembolism), malignant neoplasms (endometrial cancer, breast cancer), probable dementia (use >65 years), gallbladder disease, hypercalcemia, visual abnormalities, elevated blood pressure, hereditary angioedema, hypertriglyceridemia, fluid retention, hypothyroidism, exacerbation of asthma, diabetes mellitus, epilepsy, migraine, porphyria, SLE, hepatic hemangiomas, and conditions aggravated by fluid retention.
Undiagnosed abnormal genital bleeding; known, suspected, or history of breast cancer; known or suspected estrogen-dependent neoplasia; active or past history of venous thromboembolism; active or recent arterial thromboembolic disease (e.g., stroke, MI); liver dysfunction or disease; known hypersensitivity to estrogens; known protein C, protein S, or antithrombin deficiency; and pregnancy.
Known or suspected pregnancy, undiagnosed abnormal genital bleeding, known or suspected breast cancer (except selected patients), known or suspected estrogen-dependent neoplasia, active DVT/PE or history of thromboembolic disorders, known protein C, protein S, or antithrombin deficiency, known thrombophilic disorders, active or recent arterial thromboembolic disease (e.g., stroke, MI), known liver impairment or disease, known hypersensitivity to any ingredient.
Grapefruit juice may increase estrogen levels; avoid large quantities. No other significant food interactions.
Grapefruit and grapefruit juice may increase estrogen levels; avoid large amounts. No significant food interactions reported but take with or without food consistently to maintain stable absorption.
First trimester: Estrogens are associated with a potential risk of fetal genital tract abnormalities, including congenital anomalies such as hypospadias and vaginal adenosis. Use is contraindicated in pregnancy. Second and third trimesters: Exposure may increase risk of fetal urogenital tract abnormalities, and estrogens have been linked to an elevated risk of vaginal clear cell adenocarcinoma in female offspring. Overall, use is contraindicated throughout pregnancy due to known fetal risks.
First trimester: Increased risk of congenital anomalies including cardiovascular defects and neural tube defects. Second and third trimesters: Risk of urogenital tract abnormalities, feminization of male fetus, and potential long-term reproductive effects. Use contraindicated in pregnancy.
Estropipate (ogen) is excreted into human breast milk. The milk-to-plasma ratio (M/P ratio) is not established in published literature. Exogenous estrogens may reduce milk production and quality, particularly in early postpartum. Use during breastfeeding is generally not recommended due to potential adverse effects on the infant, including jaundice and long-term effects on reproductive development. Alternative therapies should be considered.
Contraindicated during breastfeeding. Amnestrogen is excreted in breast milk; M/P ratio unknown. Potential for serious adverse effects in nursing infants including hormonal disruption.
Estropipate is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered hepatic metabolism) are not relevant due to absolute contraindication. No dose adjustments are applicable as the drug should not be used.
Not applicable as drug is contraindicated in pregnancy. No dose adjustment recommended due to avoidance of use.
OGEN 0.625 mg (estropipate) is a conjugated estrogen tablet for hormone therapy. It may increase risk of endometrial cancer; use with progestin in women with intact uterus. Monitor for thromboembolic events. Not for prevention of cardiovascular disease or dementia. Avoid in pregnancy.
Amnestrogen (estrogen-progestin combination) is used for hormone replacement therapy. Monitor for thromboembolic events; avoid in patients with history of DVT/PE. Use lowest effective dose for shortest duration. Not for use in pregnancy; contraindicated in breast cancer. May increase risk of endometrial cancer if used without progestin in women with intact uterus.
Take exactly as prescribed; do not skip doses or stop without consulting your doctor.,Report any unusual vaginal bleeding, chest pain, shortness of breath, or vision changes immediately.,Avoid smoking as it increases risk of blood clots.,Inform all healthcare providers that you are taking estrogen.,Regular breast exams and mammograms are recommended.
Take exactly as prescribed; do not skip doses.,Report immediately any signs of blood clots: sudden leg pain, chest pain, shortness of breath, or vision changes.,Avoid smoking while on this medication; increases clot risk.,Do not use during pregnancy; if pregnancy occurs, stop and contact doctor.,Regular breast exams and mammograms are recommended.,May cause nausea; take with food or at bedtime.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OGEN .625 vs AMNESTROGEN, answered by our medical review team.
OGEN .625 is a Estrogen that works by Estrogen replacement therapy; estrogen binds to estrogen receptors, which then translocate to the nucleus and modulate gene transcription, leading to effects such as proliferation of the endometrium and regulation of gonadotropin secretion.. AMNESTROGEN is a Estrogen that works by Estrogen replacement therapy; binds to estrogen receptors, activating gene transcription and promoting development and maintenance of female reproductive tissues and secondary sex characteristics.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OGEN .625 and AMNESTROGEN depend on the specific clinical indication. These are both Estrogen agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OGEN .625 is: 0.625 mg orally once daily. The standard adult dose of AMNESTROGEN is: 1 tablet (2.5 mg estradiol and 0.625 mg norgestimate) orally once daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OGEN .625 and AMNESTROGEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OGEN .625 is classified as Category C. First trimester: Estrogens are associated with a potential risk of fetal genital tract abnormalities, including congenital anomalies such as hypospadias and vaginal adenosis. Use i. AMNESTROGEN is classified as Category C. First trimester: Increased risk of congenital anomalies including cardiovascular defects and neural tube defects. Second and third trimesters: Risk of urogenital tract abnormalitie. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.